GE HealthCare Technologies Inc.
HealthcareNASDAQ:GEHC · NASDAQ Global Select
+$0.48 today
Vol 1.76M · Avg 4.89M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
20.1%
avg 27.7%
ROIC
8.8%
avg 8.0%
ROA
5.6%
avg 12.7%
Analysis
ROE is currently the strongest return metric at 20.1% versus its period average of 27.7%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Peter J. Arduini | President, Chief Executive Officer & Director | $3.68M | — | 61 | $259,424.00 | 0.06% |
Frank R. Jimenez | General Counsel & Corporate Secretary | $1.91M | — | 61 | $93,932.00 | 0.02% |
Taha Kass-Hout | Chief Science & Technology Officer | $1.90M | — | 54 | $92,909.00 | 0.02% |
James K. Saccaro | Vice President & Chief Financial Officer | $1.89M | — | 53 | $87,471.00 | 0.02% |
Adam Holton | Chief People Officer | $1.78M | — | 55 | $14,348.00 | <0.01% |
Jeannette Bankes | President & Chief Executive Officer of Patient Care Solutions | $1.14M | — | 55 | $38,357.00 | <0.01% |
George Andrew Newcomb | Controller & Chief Accounting Officer | — | — | 59 | $10,627.00 | <0.01% |
Jahid Khandaker | Chief Information Officer | — | — | 54 | — | — |
Rana Strellis | Chief Corporate Marketing & Communications Officer | — | — | — | — | — |
Kevin Michael O'Neill | President & Chief Executive Officer of Pharmaceutical Diagnostics | — | — | 57 | $14,363.00 | <0.01% |
Carolynne Borders | Chief Investor Relations Officer | — | — | — | — | — |
Kenneth R. Stacherski | Chief Global Supply Chain & Service Officer | — | — | 54 | $41,430.00 | <0.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
8
$6.42M
Sells
0
$0.00
Net Sentiment
+$6.42M
Net buying
Most Active
Lobo Kevin
1 transactions
Analysis
Insiders reported 8 buys worth $6.42M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $6.42M. Lobo Kevin was the most active insider with 1 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | -11.9% | +14.5% (6yr)3 analysts |
| Revenue | N/A | N/A | +4.4% | +4.7% (6yr)9 analysts |
| Net Income | N/A | N/A | -51.6% | +12.3% (6yr)9 analysts |
| EBIT | N/A | N/A | -3.6% | +8.3% (6yr)9 analysts |
Analysis
Recent growth has been strongest in Revenue at +4.4% over three years. Forward estimates point to EPS at +14.5% (6yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Cardinal Health, Inc.
NYSE:CAH
$52.48B
Humana Inc.
NYSE:HUM
$45.34B
Agilent Technologies, Inc.
NYSE:A
$36.61B
Alcon Inc.
NYSE:ALC
$32.54B
IQVIA Holdings Inc.
NYSE:IQV
$29.96B
BeOne Medicines Ltd.
NASDAQ:ONC
$28.29B
ResMed Inc.
NYSE:RMD
$28.06B
Koninklijke Philips N.V.
NYSE:PHG
$25.66B
Mettler-Toledo International Inc.
NYSE:MTD
$22.91B
Insmed Incorporated
NASDAQ:INSM
$21.23B
Who manages GEHC?
GE HealthCare Technologies Inc. (GEHC) lists 12 active executives. The top listed executive is George Andrew Newcomb, Controller & Chief Accounting Officer.
Are GEHC insiders buying or selling?
Recent insider activity shows net buying of $13.94M.
Explore More
Continue the stock analysis
Jump to another research area for this company.